These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18472968)

  • 21. Angiogenesis - still a worthwhile target for breast cancer therapy?
    Lord S; Harris AL
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S19. PubMed ID: 21172081
    [No Abstract]   [Full Text] [Related]  

  • 22. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H
    Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.
    Raatschen HJ; Fu Y; Brasch RC; Pietsch H; Shames DM; Yeh BM
    Invest Radiol; 2009 May; 44(5):265-70. PubMed ID: 19346961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
    Wedam SB; Low JA; Yang SX; Chow CK; Choyke P; Danforth D; Hewitt SM; Berman A; Steinberg SM; Liewehr DJ; Plehn J; Doshi A; Thomasson D; McCarthy N; Koeppen H; Sherman M; Zujewski J; Camphausen K; Chen H; Swain SM
    J Clin Oncol; 2006 Feb; 24(5):769-77. PubMed ID: 16391297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiogenesis as a therapeutic target in breast cancer.
    Koutras AK; Starakis I; Lymperatou D; Kalofonos HP
    Mini Rev Med Chem; 2012 Oct; 12(12):1230-8. PubMed ID: 22512568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.
    Yee AJ; Akens M; Yang BL; Finkelstein J; Zheng PS; Deng Z; Yang B
    Breast Cancer Res; 2007; 9(4):R47. PubMed ID: 17662123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
    Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
    Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis influences osteogenic but not angiogenic response during bone defect healing in a rat model.
    Liu Y; Cao L; Ray S; Thormann U; Hillengass J; Delorme S; Schnettler R; Alt V; Bäuerle T
    Injury; 2013 Jul; 44(7):923-9. PubMed ID: 23522092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
    Otsuka S; Hanibuchi M; Ikuta K; Yano S; Goto H; Ogino H; Yamada T; Kakiuchi S; Nishioka Y; Takahashi T; Sone S
    Oncol Res; 2009; 17(11-12):581-91. PubMed ID: 19806789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles.
    Miles D
    Drugs; 2007; 67(12):1800-1. PubMed ID: 17683177
    [No Abstract]   [Full Text] [Related]  

  • 38. Bevacizumab in the treatment of colorectal cancer.
    Cilley JC; Barfi K; Benson AB; Mulcahy MF
    Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
    Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
    J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.